Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative ECX chemotherapy with or without bevacizumab for operable gastric and gastro-oesophageal junction adenocarcinoma
ISRCTN46020948Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jan 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, epirubicin, cisplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Medical Research Council. Primary endpoints: Safety and Overall survival. Started Jan 2007; status: completed.
02
Drugs
bevacizumabepirubicincisplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ISRCTN46020948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN46020948.